Google
RPRX 株価分析 — ROYALTY PHARMA PLC (Healthcare >> Biotechnology)
RPRX に関するよくある質問
RPRXのPER（株価収益率）は？
ROYALTY PHARMA PLC（RPRX）は現在PER 41.07倍で取引されています。
RPRXのROE（自己資本利益率）は？
ROYALTY PHARMA PLCのROEは12.01%です。
RPRXの配当利回りは？
ROYALTY PHARMA PLCの配当利回りは1.51%です。
RPRXの品質スコア（Quality Score）は？
当社のAIはRPRXの総合財務品質を100点中85点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
RPRXは今が買い時ですか？
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
RPRXはどのセクターに属しますか？
ROYALTY PHARMA PLCはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
RPRX AI Analysis Summary
Our AI summary for RPRX: ROYALTY PHARMA PLC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 41.07, ROE of 12.01%, a dividend yield of 1.51%. Its financial Quality Score stands at 85/100 — fundamentals stronger than most of the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 58.43
Price
-0.59
(-1.00%)
Day Change
|
|
|---|
RPRX, ファンダメンタルスコアはvery good ( ファンダメンタル = 85) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROEが低い
ROAがROEに比べて低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is good , ...
| Deepscope 分析 |
|
52% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
2427
|
| Magic Formula Rank by ROE |
2427
|
| Magic Formula Rank by ROIC |
2558
|
| Price | 58.43 |
| PBV / Sector |
3.42 / 5.20
|
| Earning Per Share | 1.42 |
| PE / Sector |
41.07 / 19.97
|
| PEG or PE/Growth / Sector |
0.05 / 1.22
GREAT
|
| Average 1M Daily Value |
153.24 M
GREAT
|
| Average 1W Daily Value |
142.81 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
47% |
| ポイントになる統計 |
|
77% |
| 配当 |
|
12% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:25 |
| Symbol | RPRX |
| Name | ROYALTY PHARMA PLC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 443.27 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 33,985.62 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 110 East 59th Street, New York, NY, United States, 10022
Phone: 212 883 0200
Website: https://www.royaltypharma.com
Employees: 100
Sector: Healthcare >> Biotechnology
Description: Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
